Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 35 entries
Sorted by: Best Match Show Resources per page
Antibiotic resistance among .

Infection and drug resistance

Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes I, Crowley JJ, Baker LH, Xi C.
PMID: 28331349
Infect Drug Resist. 2017 Mar 10;10:85-90. doi: 10.2147/IDR.S123798. eCollection 2017.

RESULTS: Seventy-six isolates were recovered from gastric biopsies. Clinical isolates showed evidence of antibiotic resistance to 1 (27.6%, n=21/76), 2 (28.9%, n=22/76), or ≥3 antibiotics (40.8%). Of 76 isolates, eight (10.5%) were resistant to amoxicillin and clarithromycin, which are...

Cite
Boehnke KF, Valdivieso M, Bussalleu A, et al. Antibiotic resistance among . Infect Drug Resist. 2017;10:85-90doi: 10.2147/IDR.S123798.
Boehnke, K. F., Valdivieso, M., Bussalleu, A., Sexton, R., Thompson, K. C., Osorio, S., Novoa Reyes, I., Crowley, J. J., Baker, L. H., & Xi, C. (2017). Antibiotic resistance among . Infection and drug resistance, 1085-90. https://doi.org/10.2147/IDR.S123798
Boehnke, Kevin F, et al. "Antibiotic resistance among ." Infection and drug resistance vol. 10 (2017): 85-90. doi: https://doi.org/10.2147/IDR.S123798
Boehnke KF, Valdivieso M, Bussalleu A, Sexton R, Thompson KC, Osorio S, Novoa Reyes I, Crowley JJ, Baker LH, Xi C. Antibiotic resistance among . Infect Drug Resist. 2017 Mar 10;10:85-90. doi: 10.2147/IDR.S123798. eCollection 2017. PMID: 28331349; PMCID: PMC5354526.
Copy Download .nbib Format: NLM
Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial.

The journal of prevention of Alzheimer's disease

Abner EL, Kryscio RJ, Caban-Holt AM, Schmitt FA.
PMID: 26180776
J Prev Alzheimers Dis. 2015 Mar;2(1):11-16. doi: 10.14283/jpad.2015.37.

BACKGROUND: Subjective memory complaints reflect patient-identified deficits in memory and have been linked to increased risk of future dementia in nondemented (including cognitively intact) older adults.OBJECTIVES: To assess the risk of incident dementia during follow-up for participants in the...

Cite
Abner EL, Kryscio RJ, Caban-Holt AM, et al. Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial. J Prev Alzheimers Dis. 2015;2(1):11-16doi: 10.14283/jpad.2015.37.
Abner, E. L., Kryscio, R. J., Caban-Holt, A. M., & Schmitt, F. A. (2015). Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial. The journal of prevention of Alzheimer's disease, 2(1), 11-16. https://doi.org/10.14283/jpad.2015.37
Abner, E L, et al. "Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial." The journal of prevention of Alzheimer's disease vol. 2,1 (2015): 11-16. doi: https://doi.org/10.14283/jpad.2015.37
Abner EL, Kryscio RJ, Caban-Holt AM, Schmitt FA. Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial. J Prev Alzheimers Dis. 2015 Mar;2(1):11-16. doi: 10.14283/jpad.2015.37. PMID: 26180776; PMCID: PMC4500536.
Copy Download .nbib Format: NLM
Genetic architectures of proximal and distal colorectal cancer are partly distinct.

Gut

Huyghe JR, Harrison TA, Bien SA, Hampel H, Figueiredo JC, Schmit SL, Conti DV, Chen S, Qu C, Lin Y, Barfield R, Baron JA, Cross AJ, Diergaarde B, Duggan D, Harlid S, Imaz L, Kang HM, Levine DM, Perduca V, Perez-Cornago A, Sakoda LC, Schumacher FR, Slattery ML, Toland AE, van Duijnhoven FJB, Van Guelpen B, Agudo A, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Banbury BL, Bassik MC, Berndt SI, Bézieau S, Bishop DT, Boehm J, Boeing H, Boutron-Ruault MC, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Caan BJ, Campbell PT, Carr PR, Castells A, Castellví-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Curtis KR, de la Chapelle A, Easton DF, English DR, Feskens EJM, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Jenab M, Jenkins MA, Joshi AD, Keku TO, Kooperberg C, Kühn T, Küry S, Le Marchand L, Lejbkowicz F, Li CI, Li L, Lieb W, Lindblom A, Lindor NM, Männistö S, Markowitz SD, Milne RL, Moreno L, Murphy N, Nassir R, Offit K, Ogino S, Panico S, Parfrey PS, Pearlman R, Pharoah PDP, Phipps AI, Platz EA, Potter JD, Prentice RL, Qi L, Raskin L, Rennert G, Rennert HS, Riboli E, Schafmayer C, Schoen RE, Seminara D, Song M, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Trichopoulou A, Ulrich CM, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Wolk A, Woods MO, Wu AH, Abecasis GR, Nickerson DA, Scacheri PC, Kundaje A, Casey G, Gruber SB, Hsu L, Moreno V, Hayes RB, Newcomb PA, Peters U.
PMID: 33632709
Gut. 2021 Jul;70(7):1325-1334. doi: 10.1136/gutjnl-2020-321534. Epub 2021 Feb 25.

OBJECTIVE: An understanding of the etiologic heterogeneity of colorectal cancer (CRC) is critical for improving precision prevention, including individualized screening recommendations and the discovery of novel drug targets and repurposable drug candidates for chemoprevention. Known differences in molecular characteristics...

Cite
Huyghe JR, Harrison TA, Bien SA, et al. Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut. 2021;70(7):1325-1334doi: 10.1136/gutjnl-2020-321534.
Huyghe, J. R., Harrison, T. A., Bien, S. A., Hampel, H., Figueiredo, J. C., Schmit, S. L., Conti, D. V., Chen, S., Qu, C., Lin, Y., Barfield, R., Baron, J. A., Cross, A. J., Diergaarde, B., Duggan, D., Harlid, S., Imaz, L., Kang, H. M., Levine, D. M., Perduca, V., Perez-Cornago, A., Sakoda, L. C., Schumacher, F. R., Slattery, M. L., Toland, A. E., van Duijnhoven, F. J. B., Van Guelpen, B., Agudo, A., Albanes, D., Alonso, M. H., Anderson, K., Arnau-Collell, C., Arndt, V., Banbury, B. L., Bassik, M. C., Berndt, S. I., Bézieau, S., Bishop, D. T., Boehm, J., Boeing, H., Boutron-Ruault, M. C., Brenner, H., Brezina, S., Buch, S., Buchanan, D. D., Burnett-Hartman, A., Caan, B. J., Campbell, P. T., Carr, P. R., Castells, A., Castellví-Bel, S., Chan, A. T., Chang-Claude, J., Chanock, S. J., Curtis, K. R., de la Chapelle, A., Easton, D. F., English, D. R., Feskens, E. J. M., Gala, M., Gallinger, S. J., Gauderman, W. J., Giles, G. G., Goodman, P. J., Grady, W. M., Grove, J. S., Gsur, A., Gunter, M. J., Haile, R. W., Hampe, J., Hoffmeister, M., Hopper, J. L., Hsu, W. L., Huang, W. Y., Hudson, T. J., Jenab, M., Jenkins, M. A., Joshi, A. D., Keku, T. O., Kooperberg, C., Kühn, T., Küry, S., Le Marchand, L., Lejbkowicz, F., Li, C. I., Li, L., Lieb, W., Lindblom, A., Lindor, N. M., Männistö, S., Markowitz, S. D., Milne, R. L., Moreno, L., Murphy, N., Nassir, R., Offit, K., Ogino, S., Panico, S., Parfrey, P. S., Pearlman, R., Pharoah, P. D. P., Phipps, A. I., Platz, E. A., Potter, J. D., Prentice, R. L., Qi, L., Raskin, L., Rennert, G., Rennert, H. S., Riboli, E., Schafmayer, C., Schoen, R. E., Seminara, D., Song, M., Su, Y. R., Tangen, C. M., Thibodeau, S. N., Thomas, D. C., Trichopoulou, A., Ulrich, C. M., Visvanathan, K., Vodicka, P., Vodickova, L., Vymetalkova, V., Weigl, K., Weinstein, S. J., White, E., Wolk, A., Woods, M. O., Wu, A. H., Abecasis, G. R., Nickerson, D. A., Scacheri, P. C., Kundaje, A., Casey, G., Gruber, S. B., Hsu, L., Moreno, V., Hayes, R. B., Newcomb, P. A., & Peters, U. (2021). Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut, 70(7), 1325-1334. https://doi.org/10.1136/gutjnl-2020-321534
Huyghe, Jeroen R, et al. "Genetic architectures of proximal and distal colorectal cancer are partly distinct." Gut vol. 70,7 (2021): 1325-1334. doi: https://doi.org/10.1136/gutjnl-2020-321534
Huyghe JR, Harrison TA, Bien SA, Hampel H, Figueiredo JC, Schmit SL, Conti DV, Chen S, Qu C, Lin Y, Barfield R, Baron JA, Cross AJ, Diergaarde B, Duggan D, Harlid S, Imaz L, Kang HM, Levine DM, Perduca V, Perez-Cornago A, Sakoda LC, Schumacher FR, Slattery ML, Toland AE, van Duijnhoven FJB, Van Guelpen B, Agudo A, Albanes D, Alonso MH, Anderson K, Arnau-Collell C, Arndt V, Banbury BL, Bassik MC, Berndt SI, Bézieau S, Bishop DT, Boehm J, Boeing H, Boutron-Ruault MC, Brenner H, Brezina S, Buch S, Buchanan DD, Burnett-Hartman A, Caan BJ, Campbell PT, Carr PR, Castells A, Castellví-Bel S, Chan AT, Chang-Claude J, Chanock SJ, Curtis KR, de la Chapelle A, Easton DF, English DR, Feskens EJM, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Goodman PJ, Grady WM, Grove JS, Gsur A, Gunter MJ, Haile RW, Hampe J, Hoffmeister M, Hopper JL, Hsu WL, Huang WY, Hudson TJ, Jenab M, Jenkins MA, Joshi AD, Keku TO, Kooperberg C, Kühn T, Küry S, Le Marchand L, Lejbkowicz F, Li CI, Li L, Lieb W, Lindblom A, Lindor NM, Männistö S, Markowitz SD, Milne RL, Moreno L, Murphy N, Nassir R, Offit K, Ogino S, Panico S, Parfrey PS, Pearlman R, Pharoah PDP, Phipps AI, Platz EA, Potter JD, Prentice RL, Qi L, Raskin L, Rennert G, Rennert HS, Riboli E, Schafmayer C, Schoen RE, Seminara D, Song M, Su YR, Tangen CM, Thibodeau SN, Thomas DC, Trichopoulou A, Ulrich CM, Visvanathan K, Vodicka P, Vodickova L, Vymetalkova V, Weigl K, Weinstein SJ, White E, Wolk A, Woods MO, Wu AH, Abecasis GR, Nickerson DA, Scacheri PC, Kundaje A, Casey G, Gruber SB, Hsu L, Moreno V, Hayes RB, Newcomb PA, Peters U. Genetic architectures of proximal and distal colorectal cancer are partly distinct. Gut. 2021 Jul;70(7):1325-1334. doi: 10.1136/gutjnl-2020-321534. Epub 2021 Feb 25. PMID: 33632709; PMCID: PMC8223655.
Copy Download .nbib Format: NLM
Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors.

Journal of the National Cancer Institute

Hershman DL, Neugut AI, Moseley A, Arnold KB, Gralow JR, Henry NL, Hillyer GC, Ramsey SD, Unger JM.
PMID: 33629114
J Natl Cancer Inst. 2021 Aug 02;113(8):989-996. doi: 10.1093/jnci/djab022.

BACKGROUND: Nonadherence to aromatase inhibitors (AIs) is common and increases risk of breast cancer (BC) recurrence. We analyzed factors associated with nonadherence among patients enrolled in S1105, a randomized trial of text messaging.METHODS: At enrollment, patients were required to...

Cite
Hershman DL, Neugut AI, Moseley A, et al. Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. J Natl Cancer Inst. 2021;113(8):989-996doi: 10.1093/jnci/djab022.
Hershman, D. L., Neugut, A. I., Moseley, A., Arnold, K. B., Gralow, J. R., Henry, N. L., Hillyer, G. C., Ramsey, S. D., & Unger, J. M. (2021). Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. Journal of the National Cancer Institute, 113(8), 989-996. https://doi.org/10.1093/jnci/djab022
Hershman, Dawn L, et al. "Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors." Journal of the National Cancer Institute vol. 113,8 (2021): 989-996. doi: https://doi.org/10.1093/jnci/djab022
Hershman DL, Neugut AI, Moseley A, Arnold KB, Gralow JR, Henry NL, Hillyer GC, Ramsey SD, Unger JM. Patient-Reported Outcomes and Long-Term Nonadherence to Aromatase Inhibitors. J Natl Cancer Inst. 2021 Aug 02;113(8):989-996. doi: 10.1093/jnci/djab022. PMID: 33629114; PMCID: PMC8328987.
Copy Download .nbib Format: NLM
A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer.

Genome medicine

López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, Gómez-Rubio P, Lawlor R, Carrato A, Hidalgo M, Iglesias M, Molero X, Löhr M, Michalski C, Perea J, O'Rorke M, Barberà VM, Tardón A, Farré A, Muñoz-Bellvís L, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress T, Greenhalf W, Sharp L, Arnes L, Cecchini L, Balsells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Márquez M, Mora J, O'Driscoll D, Scarpa A, Ye W, Yu J, García-Closas M, Kogevinas M, Rothman N, Silverman DT, Albanes D, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Du M, Gallinger S, Gaziano JM, Goodman PJ, Gunter M, LeMarchand L, Li D, Neale RE, Peters U, Petersen GM, Risch HA, Sánchez MJ, Shu XO, Thornquist MD, Visvanathan K, Zheng W, Chanock SJ, Easton D, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Marti-Renom MA, Real FX, Malats N.
PMID: 33517887
Genome Med. 2021 Feb 01;13(1):15. doi: 10.1186/s13073-020-00816-4.

BACKGROUND: Pancreatic cancer (PC) is a complex disease in which both non-genetic and genetic factors interplay. To date, 40 GWAS hits have been associated with PC risk in individuals of European descent, explaining 4.1% of the phenotypic variance.METHODS: We...

Cite
López de Maturana E, Rodríguez JA, Alonso L, et al. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med. 2021;13(1):15doi: 10.1186/s13073-020-00816-4.
López de Maturana, E., Rodríguez, J. A., Alonso, L., Lao, O., Molina-Montes, E., Martín-Antoniano, I. A., Gómez-Rubio, P., Lawlor, R., Carrato, A., Hidalgo, M., Iglesias, M., Molero, X., Löhr, M., Michalski, C., Perea, J., O'Rorke, M., Barberà, V. M., Tardón, A., Farré, A., Muñoz-Bellvís, L., Crnogorac-Jurcevic, T., Domínguez-Muñoz, E., Gress, T., Greenhalf, W., Sharp, L., Arnes, L., Cecchini, L., Balsells, J., Costello, E., Ilzarbe, L., Kleeff, J., Kong, B., Márquez, M., Mora, J., O'Driscoll, D., Scarpa, A., Ye, W., Yu, J., García-Closas, M., Kogevinas, M., Rothman, N., Silverman, D. T., Albanes, D., Arslan, A. A., Beane-Freeman, L., Bracci, P. M., Brennan, P., Bueno-de-Mesquita, B., Buring, J., Canzian, F., Du, M., Gallinger, S., Gaziano, J. M., Goodman, P. J., Gunter, M., LeMarchand, L., Li, D., Neale, R. E., Peters, U., Petersen, G. M., Risch, H. A., Sánchez, M. J., Shu, X. O., Thornquist, M. D., Visvanathan, K., Zheng, W., Chanock, S. J., Easton, D., Wolpin, B. M., Stolzenberg-Solomon, R. Z., Klein, A. P., Amundadottir, L. T., Marti-Renom, M. A., Real, F. X., & Malats, N. (2021). A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome medicine, 13(1), 15. https://doi.org/10.1186/s13073-020-00816-4
López de Maturana, Evangelina, et al. "A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer." Genome medicine vol. 13,1 (2021): 15. doi: https://doi.org/10.1186/s13073-020-00816-4
López de Maturana E, Rodríguez JA, Alonso L, Lao O, Molina-Montes E, Martín-Antoniano IA, Gómez-Rubio P, Lawlor R, Carrato A, Hidalgo M, Iglesias M, Molero X, Löhr M, Michalski C, Perea J, O'Rorke M, Barberà VM, Tardón A, Farré A, Muñoz-Bellvís L, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Gress T, Greenhalf W, Sharp L, Arnes L, Cecchini L, Balsells J, Costello E, Ilzarbe L, Kleeff J, Kong B, Márquez M, Mora J, O'Driscoll D, Scarpa A, Ye W, Yu J, García-Closas M, Kogevinas M, Rothman N, Silverman DT, Albanes D, Arslan AA, Beane-Freeman L, Bracci PM, Brennan P, Bueno-de-Mesquita B, Buring J, Canzian F, Du M, Gallinger S, Gaziano JM, Goodman PJ, Gunter M, LeMarchand L, Li D, Neale RE, Peters U, Petersen GM, Risch HA, Sánchez MJ, Shu XO, Thornquist MD, Visvanathan K, Zheng W, Chanock SJ, Easton D, Wolpin BM, Stolzenberg-Solomon RZ, Klein AP, Amundadottir LT, Marti-Renom MA, Real FX, Malats N. A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Med. 2021 Feb 01;13(1):15. doi: 10.1186/s13073-020-00816-4. PMID: 33517887; PMCID: PMC7849104.
Copy Download .nbib Format: NLM
Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

Tang H, Jiang L, Stolzenberg-Solomon RZ, Arslan AA, Beane Freeman LE, Bracci PM, Brennan P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Andreotti G, Babic A, Bamlet WR, Berndt SI, Blackford A, Bueno-de-Mesquita B, Buring JE, Campa D, Chanock SJ, Childs E, Duell EJ, Fuchs C, Gaziano JM, Goggins M, Hartge P, Hassam MH, Holly EA, Hoover RN, Hung RJ, Kurtz RC, Lee IM, Malats N, Milne RL, Ng K, Oberg AL, Orlow I, Peters U, Porta M, Rabe KG, Rothman N, Scelo G, Sesso HD, Silverman DT, Thompson IM, Tjønneland A, Trichopoulou A, Wactawski-Wende J, Wentzensen N, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Amundadottir LT, Jacobs EJ, Petersen GM, Wolpin BM, Risch HA, Chatterjee N, Klein AP, Li D, Kraft P, Wei P.
PMID: 32546605
Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1784-1791. doi: 10.1158/1055-9965.EPI-20-0275. Epub 2020 Jun 16.

BACKGROUND: Obesity and diabetes are major modifiable risk factors for pancreatic cancer. Interactions between genetic variants and diabetes/obesity have not previously been comprehensively investigated in pancreatic cancer at the genome-wide level.METHODS: We conducted a gene-environment interaction (GxE) analysis including...

Cite
Tang H, Jiang L, Stolzenberg-Solomon RZ, et al. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiol Biomarkers Prev. 2020;29(9):1784-1791doi: 10.1158/1055-9965.EPI-20-0275.
Tang, H., Jiang, L., Stolzenberg-Solomon, R. Z., Arslan, A. A., Beane Freeman, L. E., Bracci, P. M., Brennan, P., Canzian, F., Du, M., Gallinger, S., Giles, G. G., Goodman, P. J., Kooperberg, C., Le Marchand, L., Neale, R. E., Shu, X. O., Visvanathan, K., White, E., Zheng, W., Albanes, D., Andreotti, G., Babic, A., Bamlet, W. R., Berndt, S. I., Blackford, A., Bueno-de-Mesquita, B., Buring, J. E., Campa, D., Chanock, S. J., Childs, E., Duell, E. J., Fuchs, C., Gaziano, J. M., Goggins, M., Hartge, P., Hassam, M. H., Holly, E. A., Hoover, R. N., Hung, R. J., Kurtz, R. C., Lee, I. M., Malats, N., Milne, R. L., Ng, K., Oberg, A. L., Orlow, I., Peters, U., Porta, M., Rabe, K. G., Rothman, N., Scelo, G., Sesso, H. D., Silverman, D. T., Thompson, I. M., Tjønneland, A., Trichopoulou, A., Wactawski-Wende, J., Wentzensen, N., Wilkens, L. R., Yu, H., Zeleniuch-Jacquotte, A., Amundadottir, L. T., Jacobs, E. J., Petersen, G. M., Wolpin, B. M., Risch, H. A., Chatterjee, N., Klein, A. P., Li, D., Kraft, P., & Wei, P. (2020). Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 29(9), 1784-1791. https://doi.org/10.1158/1055-9965.EPI-20-0275
Tang, Hongwei, et al. "Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia." Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology vol. 29,9 (2020): 1784-1791. doi: https://doi.org/10.1158/1055-9965.EPI-20-0275
Tang H, Jiang L, Stolzenberg-Solomon RZ, Arslan AA, Beane Freeman LE, Bracci PM, Brennan P, Canzian F, Du M, Gallinger S, Giles GG, Goodman PJ, Kooperberg C, Le Marchand L, Neale RE, Shu XO, Visvanathan K, White E, Zheng W, Albanes D, Andreotti G, Babic A, Bamlet WR, Berndt SI, Blackford A, Bueno-de-Mesquita B, Buring JE, Campa D, Chanock SJ, Childs E, Duell EJ, Fuchs C, Gaziano JM, Goggins M, Hartge P, Hassam MH, Holly EA, Hoover RN, Hung RJ, Kurtz RC, Lee IM, Malats N, Milne RL, Ng K, Oberg AL, Orlow I, Peters U, Porta M, Rabe KG, Rothman N, Scelo G, Sesso HD, Silverman DT, Thompson IM, Tjønneland A, Trichopoulou A, Wactawski-Wende J, Wentzensen N, Wilkens LR, Yu H, Zeleniuch-Jacquotte A, Amundadottir LT, Jacobs EJ, Petersen GM, Wolpin BM, Risch HA, Chatterjee N, Klein AP, Li D, Kraft P, Wei P. Genome-Wide Gene-Diabetes and Gene-Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiol Biomarkers Prev. 2020 Sep;29(9):1784-1791. doi: 10.1158/1055-9965.EPI-20-0275. Epub 2020 Jun 16. PMID: 32546605; PMCID: PMC7483330.
Copy Download .nbib Format: NLM
Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years.

Cancer

Unger JM, Beauchemin M, Hershman DL.
PMID: 34351619
Cancer. 2021 Dec 15;127(24):4574-4584. doi: 10.1002/cncr.33855. Epub 2021 Aug 05.

BACKGROUND: Adolescent and young adult (AYA) patients with cancer have not seen the same improvements in survival as younger (pediatric) patients and older patients (adults 40 years old or older). This may be related to their lower participation in...

Cite
Unger JM, Beauchemin M, Hershman DL. Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years. Cancer. 2021;127(24):4574-4584doi: 10.1002/cncr.33855.
Unger, J. M., Beauchemin, M., & Hershman, D. L. (2021). Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years. Cancer, 127(24), 4574-4584. https://doi.org/10.1002/cncr.33855
Unger, Joseph M, et al. "Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years." Cancer vol. 127,24 (2021): 4574-4584. doi: https://doi.org/10.1002/cncr.33855
Unger JM, Beauchemin M, Hershman DL. Adolescent and young adult enrollment to a National Cancer Institute-sponsored National Clinical Trials Network Research Group over 25 years. Cancer. 2021 Dec 15;127(24):4574-4584. doi: 10.1002/cncr.33855. Epub 2021 Aug 05. PMID: 34351619; PMCID: PMC8665001.
Copy Download .nbib Format: NLM
A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013.

Journal of patient-reported outcomes

Wong SF, Unger JM, Wade JL, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM.
PMID: 32642992
J Patient Rep Outcomes. 2020 Jul 08;4(1):54. doi: 10.1186/s41687-020-00220-x.

BACKGROUND: Papulopustular rash is a common class effect of epidermal growth factor receptor inhibitors (EGFRI) that can affect patients' health-related quality of life and cause disruptions to treatment. SWOG S1013 (NCT01416688) is a multi-center study designed to validate the...

Cite
Wong SF, Unger JM, Wade JL, et al. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. J Patient Rep Outcomes. 2020;4(1):54doi: 10.1186/s41687-020-00220-x.
Wong, S. F., Unger, J. M., Wade, J. L., Wagner, L. I., Lacouture, M. E., Humphries, K. C., Moseley, A., Arnold, K., Velasco, M. R., Floyd, J. D., Esparaz, B. T., Barzi, A., Lenz, H. J., Koczywas, M., Dakhil, S., Burton, G. V., Fisch, M. J., Henry, N. L., Hershman, D. L., & Moinpour, C. M. (2020). A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. Journal of patient-reported outcomes, 4(1), 54. https://doi.org/10.1186/s41687-020-00220-x
Wong, Siu-Fun, et al. "A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013." Journal of patient-reported outcomes vol. 4,1 (2020): 54. doi: https://doi.org/10.1186/s41687-020-00220-x
Wong SF, Unger JM, Wade JL, Wagner LI, Lacouture ME, Humphries KC, Moseley A, Arnold K, Velasco MR, Floyd JD, Esparaz BT, Barzi A, Lenz HJ, Koczywas M, Dakhil S, Burton GV, Fisch MJ, Henry NL, Hershman DL, Moinpour CM. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013. J Patient Rep Outcomes. 2020 Jul 08;4(1):54. doi: 10.1186/s41687-020-00220-x. PMID: 32642992; PMCID: PMC7343679.
Copy Download .nbib Format: NLM
Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer.

JAMA oncology

Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, O'Neil BH, Mullen BC, Lenz HJ, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg RM, O'Reilly EM, Meyerhardt JA, Ng K.
PMID: 32940631
JAMA Oncol. 2020 Nov 01;6(11):1713-1721. doi: 10.1001/jamaoncol.2020.3938.

IMPORTANCE: Several compounds found in coffee possess antioxidant, anti-inflammatory, and insulin-sensitizing effects, which may contribute to anticancer activity. Epidemiological studies have identified associations between increased coffee consumption and decreased recurrence and mortality of colorectal cancer. The association between coffee...

Cite
Mackintosh C, Yuan C, Ou FS, et al. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020;6(11):1713-1721doi: 10.1001/jamaoncol.2020.3938.
Mackintosh, C., Yuan, C., Ou, F. S., Zhang, S., Niedzwiecki, D., Chang, I. W., O'Neil, B. H., Mullen, B. C., Lenz, H. J., Blanke, C. D., Venook, A. P., Mayer, R. J., Fuchs, C. S., Innocenti, F., Nixon, A. B., Goldberg, R. M., O'Reilly, E. M., Meyerhardt, J. A., & Ng, K. (2020). Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA oncology, 6(11), 1713-1721. https://doi.org/10.1001/jamaoncol.2020.3938
Mackintosh, Christopher, et al. "Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer." JAMA oncology vol. 6,11 (2020): 1713-1721. doi: https://doi.org/10.1001/jamaoncol.2020.3938
Mackintosh C, Yuan C, Ou FS, Zhang S, Niedzwiecki D, Chang IW, O'Neil BH, Mullen BC, Lenz HJ, Blanke CD, Venook AP, Mayer RJ, Fuchs CS, Innocenti F, Nixon AB, Goldberg RM, O'Reilly EM, Meyerhardt JA, Ng K. Association of Coffee Intake With Survival in Patients With Advanced or Metastatic Colorectal Cancer. JAMA Oncol. 2020 Nov 01;6(11):1713-1721. doi: 10.1001/jamaoncol.2020.3938. PMID: 32940631; PMCID: PMC7499248.
Copy Download .nbib Format: NLM
Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group.

Medical decision making : an international journal of the Society for Medical Decision Making

Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ.
PMID: 27012232
Med Decis Making. 2016 Jul;36(5):641-51. doi: 10.1177/0272989X16636847. Epub 2016 Mar 24.

OBJECTIVE: Value of information (VOI) analyses can align research with areas with the greatest potential impact on patient outcome, but questions remain concerning the feasibility and acceptability of these approaches to inform prioritization decisions. Our objective was to develop...

Cite
Bennette CS, Veenstra DL, Basu A, et al. Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Med Decis Making. 2016;36(5):641-51doi: 10.1177/0272989X16636847.
Bennette, C. S., Veenstra, D. L., Basu, A., Baker, L. H., Ramsey, S. D., & Carlson, J. J. (2016). Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Medical decision making : an international journal of the Society for Medical Decision Making, 36(5), 641-51. https://doi.org/10.1177/0272989X16636847
Bennette, Caroline S, et al. "Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group." Medical decision making : an international journal of the Society for Medical Decision Making vol. 36,5 (2016): 641-51. doi: https://doi.org/10.1177/0272989X16636847
Bennette CS, Veenstra DL, Basu A, Baker LH, Ramsey SD, Carlson JJ. Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group. Med Decis Making. 2016 Jul;36(5):641-51. doi: 10.1177/0272989X16636847. Epub 2016 Mar 24. PMID: 27012232; PMCID: PMC5963256.
Copy Download .nbib Format: NLM
Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance).

JNCI cancer spectrum

Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA.
PMID: 32259016
JNCI Cancer Spectr. 2019 Oct 17;4(1):pkz078. doi: 10.1093/jncics/pkz078. eCollection 2020 Feb.

BACKGROUND: Diabetes is a prognostic factor for some malignancies, but its association with outcome in patients with advanced or metastatic colorectal cancer (CRC) is less clear.METHODS: This cohort study was nested within a randomized trial of first-line chemotherapy and...

Cite
Brown JC, Zhang S, Ou FS, et al. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectr. 2019;4(1):pkz078doi: 10.1093/jncics/pkz078.
Brown, J. C., Zhang, S., Ou, F. S., Venook, A. P., Niedzwiecki, D., Lenz, H. J., Innocenti, F., O'Neil, B. H., Shaw, J. E., Polite, B. N., Denlinger, C. S., Atkins, J. N., Goldberg, R. M., Ng, K., Mayer, R. J., Blanke, C. D., O'Reilly, E. M., Fuchs, C. S., & Meyerhardt, J. A. (2020). Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI cancer spectrum, 4(1), pkz078. https://doi.org/10.1093/jncics/pkz078
Brown, Justin C, et al. "Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance)." JNCI cancer spectrum vol. 4,1 (2020): pkz078. doi: https://doi.org/10.1093/jncics/pkz078
Brown JC, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Denlinger CS, Atkins JN, Goldberg RM, Ng K, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA. Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). JNCI Cancer Spectr. 2019 Oct 17;4(1):pkz078. doi: 10.1093/jncics/pkz078. eCollection 2020 Feb. PMID: 32259016; PMCID: PMC7043296.
Copy Download .nbib Format: NLM
What Keeps Patients Out of Clinical Trials?.

JCO oncology practice

Minasian LM, Unger JM.
PMID: 32074016
JCO Oncol Pract. 2020 Mar;16(3):125-127. doi: 10.1200/JOP.19.00735. Epub 2020 Feb 19.

No abstract available.

Cite
Minasian LM, Unger JM. What Keeps Patients Out of Clinical Trials?. JCO Oncol Pract. 2020;16(3):125-127doi: 10.1200/JOP.19.00735.
Minasian, L. M., & Unger, J. M. (2020). What Keeps Patients Out of Clinical Trials?. JCO oncology practice, 16(3), 125-127. https://doi.org/10.1200/JOP.19.00735
Minasian, Lori M, and Unger, Joseph M. "What Keeps Patients Out of Clinical Trials?." JCO oncology practice vol. 16,3 (2020): 125-127. doi: https://doi.org/10.1200/JOP.19.00735
Minasian LM, Unger JM. What Keeps Patients Out of Clinical Trials?. JCO Oncol Pract. 2020 Mar;16(3):125-127. doi: 10.1200/JOP.19.00735. Epub 2020 Feb 19. PMID: 32074016.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 35 entries